Cellares and GenomeFrontier to assess automated GF-CART01 production

The collaboration, which marks Cellares’ first development project in Asia, will explore adapting GenomeFrontier’s virus-free process to the Cell Shuttle system.

It aims to assist GenomeFrontier’s clinical activities for GF-CART01 in the US.

GF-CART01 is being developed for a range of B-cell malignancies. Target indications include diffuse large B-cell lymphoma, follicular lymphoma, high-grade B-cell lymphoma and primary mediastinal large B-cell lymphoma.

It has shown positive clinical trial data in Taiwan, and patient recruitment is ongoing for a Phase I trial in the US.

GenomeFrontier founder, CEO and chief scientific officer Sareina Wu said: “As we advance GF-CART01, it is important that our manufacturing strategy can support both clinical development and future scale.”

The evaluation will concentrate on translating GenomeFrontier’s manufacturing technique to the Cell Shuttle platform, particularly focusing on transfection operations using Cellares’ integrated electroporator.

The companies aim to examine the feasibility of automating the process while maintaining the flexibility GenomeFrontier’s virus-free system requires.

Cellares co-founder and CEO Fabian Gerlinghaus said: “GenomeFrontier’s virus-free approach reflects the increasing complexity of next-generation cell therapy manufacturing.

“The Cell Shuttle is built to automate complex processes, including electroporation-based workflows, with the scalability and reliability needed as therapies advance through clinical development. This partnership brings that capability to GenomeFrontier as it expands its programme in the US.”

Autologous CAR-T production is typically labour-intensive, variable and challenging to scale, which affects manufacturing reliability, cost and patient access.

Cellares’ Cell Shuttle is intended to address these challenges by automating end-to-end cell therapy manufacturing.

GenomeFrontier and Cellares intend to establish whether the automated process can support the virus-free approach, with objectives to enhance reliability and reduce costs.

The post Cellares and GenomeFrontier to assess automated GF-CART01 production appeared first on Pharmaceutical Business review.